Couroucé A M
Transfus Clin Biol. 1994;1(5):387-95. doi: 10.1016/s1246-7820(06)80021-2.
The combined HIV1 + HIV2 assays allow to screen simultaneously the subjects infected by HIV1 or by HIV2 (About 80 HIV1 for 1 HIV2 in blood donations in France). An improvement of both sensitivity and specificity was obtained by using artificial proteins which have been selected for having the most immuno-dominant epitopes. The sensitivity is defined by the study of samples from recent and very recent seroconverters and the specificity by testing 2000 unselected blood donors. All the early seroconversions must be recognized as positive and less than 0.5% false positive results must be found in blood donors. HIV1 variants, temporarily named sub-type O have brought a new difficulty to the HIV serology, due to a weak homology, especially in "env" domains, between these variants and the reference HIV1 strains. Subjects living in France and infected by this HIV1 variant seem rare and the screening assays which miss some of these infected individuals seem capable to modify their reagents in order to recognize all of them.
HIV1 + HIV2联合检测可同时筛查感染HIV1或HIV2的受试者(在法国献血中,HIV1与HIV2的比例约为80:1)。通过使用已筛选出具有最具免疫优势表位的人工蛋白质,提高了检测的灵敏度和特异性。灵敏度通过对近期和极近期血清转化者的样本进行研究来确定,特异性则通过检测2000名未经筛选的献血者来确定。所有早期血清转化都必须被识别为阳性,并且在献血者中必须发现低于0.5%的假阳性结果。HIV1变异体,临时命名为O亚型,给HIV血清学带来了新的困难,因为这些变异体与参考HIV1毒株之间的同源性较弱,尤其是在“env”区域。生活在法国且感染这种HIV1变异体的受试者似乎很少见,那些遗漏部分感染者的筛查检测似乎有能力改进其试剂,以便识别所有感染者。